KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Depreciation & Amortization (CF) (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 16.91% to $5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.5 million through Dec 2025, up 1.14% year-over-year, with the annual reading at $19.5 million for FY2025, 1.14% up from the prior year.
  • Depreciation & Amortization (CF) hit $5.7 million in Q4 2025 for CRISPR Therapeutics AG, up from $4.4 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $7.3 million in Q2 2022 to a low of $2.7 million in Q1 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $5.0 million across 5 years, with a median of $4.9 million in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 144.0% in 2021 and later plummeted 31.75% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $6.3 million in 2021, then dropped by 6.63% to $5.8 million in 2022, then dropped by 16.18% to $4.9 million in 2023, then decreased by 1.18% to $4.8 million in 2024, then increased by 16.91% to $5.7 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CRSP at $5.7 million in Q4 2025, $4.4 million in Q3 2025, and $4.6 million in Q2 2025.